Breakout Stocks of Week 28
NASDAQ was up last week (week 27) by 1.94% ending at 14,639.33 points after gaining 278.94 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Equifax Inc NYSE:EFX. This stock has had a buy signal since Jun 21, 2021 when the price was $238.72 and is so far up 1.52% to $242.34. Some other companies are on our watchlist to, among these are Hikal Limited NSE:HIKAL Britvic XLON:BVIC Alexion Pharmaceuticals NASDAQ:ALXN and Alphabet Inc. NASDAQ:GOOG which all got a breakout pattern emerging.
| Date | Company | Price | Week 28 |
|---|---|---|---|
| Equifax Inc | $242.34 | $248.54 | 2.56% |
| Hikal Limited | ₹525.60 | ₹512.95 | -2.41% |
| Britvic | £963.00 | £975.00 | 1.25% |
| Alexion Pharmaceuticals | $186.28 | $184.20 | -1.12% |
| Alphabet Inc. | $128.72 | $129.57 | 0.665% |
The Equifax Inc stock price gained 0.485% on the last trading day (Friday, 2nd Jul 2021), rising from $241.17 to $242.34. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 1.31% from a day low at $241.14 to a day high of $244.29. The price has risen in 6 of the last 10 days and is up by 4.1% over the past 2 weeks. Volume fell on the last day by -58 thousand shares and in total, 614 thousand shares were bought and sold for approximately $148.91 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
On Apr 19, 2024, it was reported that Oppenheimer gave EFX a "Outperform" grade with a "hold" action.
Equifax Inc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Equifax Inc:
Equifax Inc. provides information solutions and human resources business process automation outsourcing services for businesses, governments, and consumers. The company operates through three segments: Workforce Solutions, U.S. Information Solutions (USIS), and International. The Workforce Solutions segment offers employment, income, criminal history, and social security number verification services, as well as payroll-based transaction, employment tax management, and identity theft protection products. The USIS segment provides consumer and commercial information services, such as credit information and credit scoring, credit modeling and portfolio analytics, locate, fraud detection and prevention, identity verification, and other consulting; mortgage services; financial marketing services; identity management services; credit monitoring products; and online information, decisioning technology solutions, as well as portfolio management, mortgage reporting, and consumer credit information services. The International segment offers information service products, which include consumer and commercial services, such as credit and financial information, and credit scoring and modeling; and credit and other marketing products and services, as well as offers information, technology, and other services to support debt collections and recovery management. The company serves customers in financial services, mortgage, employers, consumer, commercial, telecommunication, retail, automotive, utility, brokerage, healthcare, and insurance industries, as well as state, federal, and local governments. It operates in the United States, Canada, Australia, New Zealand, India, the United Kingdom, Spain, Portugal, Argentina, Chile, Costa Rica, Ecuador, El Salvador, Honduras, Mexico, Paraguay, Peru, Uruguay, Brazil, the Republic of Ireland, Russia, Cambodia, Malaysia, Singapore, and the United Arab Emirates. The company was founded in 1899 and is headquartered in Atlanta, Georgia.
The Hikal Limited stock price gained 6.20% on the last trading day (Friday, 2nd Jul 2021), rising from ₹494.90 to ₹525.60. It has now gained 5 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 14.95% from a day low at ₹495.00 to a day high of ₹569.00. The price has risen in 8 of the last 10 days and is up by 15.35% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 3 million more shares were traded than the day before. In total, 3 million shares were bought and sold for approximately ₹1.63 billion.
Hikal Limited holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Hikal Limited:
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides. The company collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and APIs. It also provides specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
The Britvic stock price gained 1.26% on the last trading day (Friday, 2nd Jul 2021), rising from £951.00 to £963.00. During the last trading day the stock fluctuated 1.31% from a day low at £955.00 to a day high of £967.50. The price has been going up and down for this period, and there has been a 3.72% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 19 thousand more shares were traded than the day before. In total, 448 thousand shares were bought and sold for approximately £431.40 million.
Britvic holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Britvic:
Britvic plc, together with its subsidiaries, manufactures, markets, distributes, and sells soft drinks in the United Kingdom, the Republic of Ireland, France, Brazil, and internationally. It also provides fruit juices, syrups, squash, mineral water, liquid concentrates, ready-to-drink nectar drinks, sodas, mixers, and energy and flavored drinks. The company offers its products under the 7UP, Aqua Libra, Ballygowan, Britvic, drench, Robinsons, Gatorade, J2O, Lipton, London Essence, Mathieu Teisseire, Mountain Dew, Pepsi MAX, Plenish, Purdey's, Rockstar, R. White's, Tango, Teisseire, Bela Ischia, Britvic, Dafruta, Maguary, Mathieu Teisseire, Pressade, Puro Coco, C&C, Cidona, Club, Edge, Energise Sport, MiWadi, Moulin de Valdonne, and TK brands. In addition, it supplies water-coolers and bottled water; engages in the wholesale of soft drinks to the licensed trade; offers pension funding and financing services; and designs, installs, and maintains integrated tap solutions. The company was incorporated in 2005 and is headquartered in Hemel Hempstead, the United Kingdom.
The Alexion Pharmaceuticals stock price gained 0.637% on the last trading day (Friday, 2nd Jul 2021), rising from $185.10 to $186.28. During the last trading day the stock fluctuated 1.11% from a day low at $184.47 to a day high of $186.52. The price has risen in 7 of the last 10 days and is up by 3.09% over the past 2 weeks. Volume fell on the last day by -49 thousand shares and in total, 1 million shares were bought and sold for approximately $237.01 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Alexion Pharmaceuticals holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Alexion Pharmaceuticals:
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
The Google stock price gained 1.86% on the last trading day (Friday, 2nd Jul 2021), rising from $126.37 to $128.72. During the last trading day the stock fluctuated 1.64% from a day low at $126.77 to a day high of $128.85. The price has been going up and down for this period, and there has been a 2.51% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 4 million more shares were traded than the day before. In total, 21 million shares were bought and sold for approximately $2.69 billion.
On Apr 09, 2024, it was reported that Cowen & Co. gave GOOG a "Buy" grade with a "hold" action.
Google holds several positive signals and is considered to be a good choice at current levels. We expect the stock to perform very well in the short term period.
About Alphabet Inc.:
Alphabet Inc. provides various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment offers products and services, including ads, Android, Chrome, hardware, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play store; and Fitbit wearable devices, Google Nest home products, Pixel phones, and other devices, as well as in the provision of YouTube non-advertising services. The Google Cloud segment offers infrastructure, platform, and other services; Google Workspace that include cloud-based collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells health technology and internet services. The company was founded in 1998 and is headquartered in Mountain View, California.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
